natgillin/translations-raw huggingface dataset:
The CHMP also discussed the possibility to request that further data be collected following the authorisation of the combination. 
Prav tako je obravnaval možnost, da bi po izdaji dovoljenja za uporabo kombinacije zahteval pridobitev dodatnih podatkov.
Opdivo and Yervoy are to be used together in patients with previously untreated advanced renal cell carcinoma that is considered to be of moderate or high risk of worsening. 
Zdravili Opdivo in Yervoy naj bi se uporabljali skupaj pri predhodno nezdravljenih bolnikih z napredovalim karcinomom ledvičnih celic, za katere obstaja zmerno ali veliko tveganje za poslabšanje bolezni.
On 15 November 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended that a change to the marketing authorisation for the medicinal products Opdivo (nivolumab) and Yervoy (ipilimumab) be granted. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je 15. novembra 2018 priporočil odobritev spremembe dovoljenja za promet z zdraviloma Opdivo (novolumab) in Yervoy (ipilimumab).
At the same time it was clear that combination with Yervoy resulted in more side effects than are seen with Opdivo alone. 
Hkrati je bilo jasno, da je kombinacija z zdravilom Yervoy povzročila več neželenih učinkov kot pri samostojnem zdravilu Opdivo.
On 26 July 2018, the CHMP had originally adopted a negative opinion for the use of Opdivo and Yervoy for the treatment of renal cell carcinoma. 
Odbor CHMP je 26. julija 2018 najprej sprejel negativno mnenje o uporabi zdravili Opdivo in Yervoy pri zdravljenju karcinoma ledvičnih celic.
It is already used on its own to treat renal cell carcinoma in patients who have previously been treated with other cancer medicines. 
Uporablja se kot samostojno zdravilo za zdravljenje karcinoma ledvičnih celic pri bolnikih, ki so se predhodno že zdravili z drugimi zdravili proti raku.
The active substance in both medicines, nivolumab and ipilimumab, are monoclonal antibodies, a type of protein that has been designed to recognise and attach to a specific structure. 
Učinkovini v obeh zdravilih, nivolumab in ipilimumab, sta monoklonski protitelesi (vrsti beljakovine), ki sta bili zasnovani tako, da prepoznata specifično prijemališče in se nanjo pritrdita.
The CHMP considered that the results from the main study comparing Opdivo and Yervoy with sunitinib showed a clinically important increase in patients' survival with the combination, and side effects were considered acceptable. 
Odbor CHMP je presodil, da so rezultati študije, v kateri so primerjali zdravili Opdivo in Yervoy s sunitibom, dokazali klinično pomembno podaljšanje preživetja bolnikov s kombinacijo, medtem ko so bili neželeni učinki opredeljeni kot sprejemljivi.
The change concerns the use of both medicines together to treat renal cell carcinoma (kidney cancer). 
Sprememba zadeva skupno uporabo teh zdravil pri zdravljenju karcinoma ledvičnih celic (rak ledvic).
The CHMP was of the opinion that the benefits of the combination largely outweigh its risks and therefore recommended granting the change to the marketing authorisation. 
Posledično je odbor CHMP tedaj menil, da koristi kombinacije obeh zdravil odtehtajo z njima povezana tveganja, in priporočil odobritev vloge za spremembo dovoljenja za promet.
Although improvements in survival were seen in previously untreated patients given the combination of Opdivo and Yervoy compared with sunitinib, there was no evidence showing if Yervoy contributed to these results and if so, how much. 
Čeprav je bilo pri primerjavi med zdraviloma Optivo in Yervoy ter sunitibom opaženo izboljšanje pri preživetju predhodno nezdravljenih bolnikih, ni bilo podatkov, ki bi dokazali, da je zdravilo Yervoy prispevalo k omenjenim rezultatom in če že, v kolikšni meri.
By attaching to the receptor, nivolumab prevents PD-L1 and PD-L2 from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells. 
Z vezavo na receptor učinkovina nivolumab prepreči, da bi beljakovini PD-L1 in PD-L2 onemogočili delovanje celic T, s čimer poveča sposobnost imunskega sistema za uničevanje rakavih celic.
The study compared treatment with Opdivo and Yervoy versus treatment with another cancer medicine, sunitinib. 
V njej so primerjali zdravljenje z zdravili Opdivo in Yervoy z zdravljenjem z drugim zdravilom za raka, sunitibom.
It is known that Opdivo alone produces benefit in previously treated patients with renal cell carcinoma. 
Znano je, da samostojno zdravilo Opdivo koristi bolnikom s predhodno zdravljenim karcinomom ledvičnih celic.
How do Opdivo and Yervoy work? 
Kako zdravili Opdivo in Yervoy delujeta?
Opdivo and Yervoy are cancer medicines. 
Zdravili Opdivo in Yervoy sta zdravili za zdravljenje raka.
What are Opdivo and Yervoy? 
Kaj sta zdravili Opdivo in Yervoy?
By blocking CTLA-4, ipilimumab causes activation and increase of T cells, which enter into tumours and kill the tumour cells. 
Ipilimumab z zaviranjem delovanja beljakovine CTLA-4 spodbuja delovanje in širjenje celic T, ki prodrejo v tumor in uničijo tumorske celice.
They contain the active substances nivolumab and ipilimumab respectively. 
Prvo vsebuje učinkovino nivolumab, drugo pa ipilimumab.
What are Opdivo and Yervoy to be used for? 
Za kaj naj bi se zdravili Opdivo in Yervoy uporabljali?
Ipilimumab attaches to and blocks the activity of CTLA-4, a protein that controls the activity of T cells. 
Ipilimumab se veže na beljakovino CTLA-4, ki nadzira delovanje celic T, in zavira njeno delovanje.
Cancer cells can produce proteins (PD-L1 and PD-L2) that attach to this receptor and switch off the activity of the T cells, preventing them from attacking the cancer. 
Učinkovina nivolumab se pritrdi na receptor PD-1, ki se nahaja v nekaterih celicah imunskega sistema, imenovanih celice T. Rakave celice lahko tvorijo beljakovine (PD-L1 in PD-L2), ki se vežejo na ta receptor in onemogočijo delovanje celic T, tako da te ne morejo napasti rakavih celic.
Gastro-resistant tablet 
Gastrorezistentne tablete
4.5 mg (1:1:1) film-coated tablet 
4.5 mg (1:1:1) Filmsko obložena tableta
Defiante Farmacêutica, S.A. PRT 
Portugalska Defiante Farmacêutica, S.A. PRT
CAPERGYL 4,5 mg DOSE QUOTIDIENNE UNIQUE, capsule soft capsule 
CAPERGYL 4,5 mg DOSE QUOTIDIENNE UNIQUE, capsule mehka kapsula
Verovskova 57, SI-1526 Ljubljana, Slovenia 
Verovškova 57, SI-1526 Ljubljana, Slovenia
Hydergin 3 mg/ml Tropfen 3 mg/ml (1:1:1) oral drops, solution oral use 
Hydergin 3 mg/ml Tropfen 3 mg/ml (1:1:1) peroralne kapljice, raztopina
Hydergin 1 mg/ml Tropfen 1 mg/ml (1:1:1) oral drops, solution oral use 
Hydergin 1 mg/ml Tropfen 1 mg/ml (1:1:1) peroralne kapljice, raztopina
27 May 2019 
27. maj 2019
It must also not be given to patients with epilepsy who are not adequately controlled by treatment. 
Prav tako se ne sme dajati bolnikom z epilepsijo, ki ni ustrezno nadzorovana z zdravljenjem.
It is given by injection. 
Daje se z injiciranjem.
Why was Septanest reviewed? 
Zakaj je bilo zdravilo Septanest pregledano?
The package leaflet has been updated accordingly. 
Navodilo za uporabo je bilo ustrezno posodobljeno.
Septanest has been authorised in the EU via national procedures. 
Zdravilo Septanest je bilo v EU odobreno z nacionalnimi postopki.
After review of the available data, a number of other contraindications which were only valid in some countries were considered not to be supported by sufficient data or were considered redundant. 
Po pregledu razpoložljivih podatkov je bilo za več drugih kontraindikacij, ki so veljale samo v nekaterih državah, ugotovljeno, da niso podprte z zadostnimi podatki ali so odvečne.
The maximum recommended dose in all ages is 7 mg of articaine per kg body weight, up to a maximum total dose of 500 mg in adults and 385 mg in children. 
Največji priporočeni odmerek za vse starosti je 7 mg artikaina na kilogram telesne mase do najvišjega skupnega odmerka 500 mg pri odraslih in 385 mg pri otrocih.
A European Commission decision valid throughout the EU was issued on 27/05/2019. 
Sklep Evropske komisije, ki velja po vsej EU, je bil izdan 27. maja 2019.
Septanest is also available in the EU under other trade names including Septanest Forte, Septanest N, Septanest Normal, Septanest SP, Septanest Special, Septanest with Adrenaline, Septanestepi and Septocaine. 
Zdravilo Septanest je v EU na voljo tudi pod drugimi trgovskimi imeni, med drugim Septanest Forte, Septanest N, Septanest Normal, Septanest SP, Septanest Special, Septanest z adrenalinom, Septanestepi in Septocaine.
The recommended dose of Septanest depends on the patient's body weight. 
Priporočeni odmerek zdravila Septanest je odvisen od bolnikove telesne mase.
This has led to inconsistency across Member States in the way the medicine is produced and can be used, as seen in the differences in the prescribing information - that is, the summary of product characteristics (SmPC), labelling and package leaflet - in the countries where the medicine is marketed. 
To je med državami članicami povzročilo nedoslednosti v načinu, kako se zdravilo proizvaja in lahko uporablja, kar se odraža v razlikah med informacijami o predpisovanju, tj. v povzetkih glavnih značilnosti zdravila, označevanjih in navodilih za uporabo), v državah, v katerih se zdravilo trži.
In addition, parts of Module 3 of the medicine dossier (which describes how the medicine is produced and its quality controlled) have also been harmonised. 
Poleg tega sta bila usklajena modul 3 dokumentacije o zdravilu (v katerem je opisano, kako je zdravilo proizvedeno in kako se nadzoruje njegova kakovost).
On 28 March 2019, the European Medicines Agency (EMA) completed a review of Septanest (also known by various other names) and recommended changes to the prescribing information in order to harmonise the way the medicine is used in the EU. 
Evropska agencija za zdravila (EMA) je 28. marca 2019 zaključila pregled zdravila Septanest (znanega tudi pod drugimi imeni) ter priporočila spremembe informacij o predpisovanju, da bi se uskladil način uporabe zdravila v EU.
Other harmonised sections of the SmPC include section 4.4 (special warnings and precautions for use), 4.5 (interactions), 4.6 (fertility, pregnancy and lactation), 4.7 (effects on ability to drive and use machines), 4.8 (side effects), and 4.9 (overdose). 
Druga usklajena poglavja povzetka glavnih značilnosti zdravila vključujejo poglavja 4.4 (Posebna opozorila in previdnostni ukrepi), 4.5 (Medsebojno delovanje z drugimi zdravili), 4.6 (Plodnost, nosečnost in dojenje), 4.7 (Vpliv na sposobnost vožnje in upravljanja strojev), 4.8 (Neželeni učinki) in 4.9 (Preveliko odmerjanje).
Where justified by data, some of the previous contraindications have been included in section 4.4 (special warnings and precautions for use). 
Če so bile podprte s podatki, so bile nekatere od predhodnih kontraindikacij vključene v poglavje 4.4 Posebna opozorila in previdnostni ukrepi.
The review of Septanest was initiated on 29 June 2018 at the request of the marketing authorisation holder, Septodont, under Article 30 of Directive 2001/83/EC. 
Pregled zdravila Septanest se je začel 29. junija 2018 na zahtevo imetnika dovoljenja za promet z zdravilom, podjetja Septodont, v skladu s členom 30 Direktive 2001/83/ES.
Septanest is now authorised for use as a local anaesthetic in dental procedures in adults, adolescents and children above 4 years of age (or weighing at least 20 kg). 
Zdravilo Septanest je zdaj odobreno za uporabo kot lokalni anestetik pri dentalnih kirurških posegih pri odraslih, mladostnikih in otrocih, starejših od štirih let (ali ki tehtajo vsaj 20 kg).
Septanest contains the active ingredient articaine together with adrenaline (epinephrine), which helps prolong articaine's effects and restrict it to a particular area of the body. 
Zdravilo Septanest vsebuje učinkovino artikain skupaj z adrenalinom (epinefrinom), ki pomaga podaljšati učinek artikaina in ga omejiti na določen del telesa.
Septanest must not be used in patients who are allergic to articaine or similar local anaesthetics (known as amide-type local anaesthetics) or to any other ingredient of the medicine. 
Zdravilo Septanest se ne sme uporabljati pri bolnikih, ki so alergični na artikain ali podobne lokalne anestetike (znane kot amidni lokalni anestetiki) ali na katero koli drugo sestavino zdravila.
Septanest is a local anaesthetic (a medicine for preventing pain and discomfort in a part of the body during medical procedures). 
Zdravilo Septanest je lokalni anestetik (zdravilo za preprečevanje bolečine in neugodja v delu telesa med medicinskimi postopki).
After considering the available data on the use of Septanest, the Agency concluded that the SmPC should be harmonised. 
Po pregledu razpoložljivih podatkov o uporabi zdravila Septanest je agencija zaključila, da je treba uskladiti povzetke glavnih značilnosti zdravila.
What is Septanest? 
Kaj je zdravilo Septanest?
On 4 June 2018, Septodont, the company that markets Septanest, referred the matter to EMA in order to harmonise the marketing authorisations for Septanest in the EU. 
Podjetje Septodont, ki trži zdravilo Septanest, je 4. junija 2018 zadevo napotilo na agencijo EMA, da bi se uskladila dovoljenja za promet s tem zdravilom v EU.
This is more likely at the start of treatment or if the doctor increases your dose. 
To je bolj verjetno na začetku zdravljenja ali če vam zdravnik poveča odmerek.
Your doctor has decided which dose is best for you. 
Vaš zdravnik se je odločil, kateri odmerek je za vas najprimernejši.
Follow your doctor's instructions and do not change the dose yourself. 
Upoštevajte zdravnikova navodila in ne spreminjajte odmerka sami.
• Take with or without food 
• Lahko jih jemljete s hrano ali brez nje.
Adults including the elderly 
Odrasli, vključno s starejšimi bolniki
The shell does not break down but passes through your body. 
Ovoj se ne razgradi, ampak prehaja skozi telo.
Take any remaining tablets and the container with you. 
Preostale tablete in vsebnik vzemite s seboj.
Contact your doctor or nearest hospital casualty department immediately. 
Takoj obiščite zdravnika ali najbližji bolnišnični nezgodni oddelek.
• if you are allergic to any of the tablet ingredients 
• če ste alergični na katerokoli sestavino tablet;
If it is almost time for your next dose though, do not double the dose just carry on as before. 
Če je skoraj čas za naslednji odmerek, odmerka ne podvojite, ampak jemljite tablete kot prej.
Tell your doctor if any of the above apply to you. 
Obvestite zdravnika, če karkoli od zgoraj navedenega velja za vas.
Frequencies are defined as very common (≥1/10); common (>1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10 000 to <1/1000); very rare (<1/10 
Pogostost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (> 1/100 do < 1/10), občasni (> 1/1000 do < 1/100), redki (> 1/10.000 do < 1/1000), zelo redki (< 1/10.000).
• medicine containing Estrogen 
• zdravila, ki vsebujejo estrogen;
It contains Doxazosin, which belongs to a group of medicines called alpha-blockers. 
Vsebuje doksazosin, ki spada v skupino zdravil, imenovanih alfa-blokatorji.
• other medicine to lower blood pressure 
• druga zdravila za znižanje krvnega tlaka;
In hypertensive patients both conditions are treated concomitantly. 
Pri hipertenzivnih bolnikih obe bolezni zdravimo sočasno.
UK Tel: 00 44 1707 853000 Fax: 00 44 1707 650734 
Združeno kraljestvo Tel: 00 44 1707 853000 Faks: 00 44 1707 650734
Tell your doctor if you are already taking any of the following: 
Povejte zdravniku, če že jemljete katero koli izmed naslednjih zdravil:
If necessary, your doctor may increase this dose to the maximum of two tablets once a day. 
Zdravnik po potrebi lahko poveča odmerek na največ dve tableti enkrat dnevno.
• Swallow the tablets whole with a full glass of water 
• Tablete pogoltnite cele, s polnim kozarcem vode.
Your medicine is in the form of a ‘prolonged-release' tablet. 
Vaše zdravilo je v obliki tablet s "podaljšanim sproščanjem".
Very rare effects seen in less than 1 in 10,000 patients include blood changes and an increase in blood and creatinine levels. 
Med zelo redkimi neželenimi učinki, ki so jih opazili pri manj kot 1 bolniku od 10.000, so spremembe krvi in zvišanje ravni kreatinina v krvi.
They should be informed about the potential risk form injuries and measures of precaution to minimize orthostatic symptoms. 
Treba jih je opozoriti na morebitno tveganje poškodb in obvestiti o ukrepih za zmanjševanje ortostatskih simptomov.
A dosage regime of 82mg/kg/day (8 times the human exposure) was associated with reduced foetal survival. 
Odmerki 82 mg/kg/dan (8kratna izpostavljenost pri človeku) so bili povezani z zmanjšanim preživetjem fetusov.
• if you have kidney problems such as bladder stones, difficulty passing urine or suffer from frequent urine infections. 
• če imate težave z ledvicami, kot so kamni v mehurju, težave pri uriniranju ali pogoste okužbe sečil.
Pharmacotherapeutic group: Alpha-adrenoceptor antagonists, ATC code: C02CA04 
Farmakoterapevtska skupina: zaviralci alfa-adrenergičnih receptorjev, oznaka ATC: C02CA04
Nonsteroidal antirheumatics or estrogens may reduce the antihypertensive effect of doxazosin. 
Nesteroidni antirevmatiki ali estrogeni lahko zmanjšajo antihipertenzivni učinek doksazosina.
Do not drive or operate machinery if you feel less alert while taking this medicine. 
Vpliv na sposobnost upravljanja vozil in strojev Ne vozite avtomobila ali upravljajte s stroji, če se med jemanjem tega zdravila počutite manj zbrani.
Pack sizes: 10, 20, 28, 30, 50, 56, 60, 90, 98, 100, 140 (10 x 14) tablets Calendar packs of 28 and 98 
Velikosti pakiranj: 10, 20, 28, 30, 50, 56, 60, 90, 98, 100, 140 (10 x 14) tablet.
Must not be chewed, divided or crushed. 
Ne smejo se žvečiti, prepoloviti ali zdrobiti.
Postural hypotension and in rare cases syncope may occur at the beginning of therapy, especially at very high doses but also when treatment is recommenced after a break. 
Na začetku zdravljenja lahko pride do posturalne hipotenzije in v redkih primerih do sinkope, zlasti pri zelo velikih odmerkih, vendar tudi pri ponovnem zdravljenju po premoru.
• if you have liver problems 
• če imate težave z jetri;
10 prolonged-release tablets 20 prolonged-release tablets 28 prolonged-release tablets 30 prolonged-release tablets 50 prolonged-release tablets 56 prolonged-release tablets 60 prolonged-release tablets 90 prolonged-release tablets 98 prolonged-release tablets 100 prolonged-release tablets 140 prolonged-release tablets 
10 tablet s podaljšanim sproščanjem 20 tablet s podaljšanim sproščanjem 28 tablet s podaljšanim sproščanjem 30 tablet s podaljšanim sproščanjem 50 tablet s podaljšanim sproščanjem 56 tablet s podaljšanim sproščanjem 60 tablet s podaljšanim sproščanjem 90 tablet s podaljšanim sproščanjem 98 tablet s podaljšanim sproščanjem 100 tablet s podaljšanim sproščanjem 140 tablet s podaljšanim sproščanjem
Studies in lactating rats given a single oral dose of radioactive doxazosin gave an accumulation in breast milk with a maximum concentration of about 20 times greater than the maternal plasma concentration. 
V študijah na doječih podganah, ki so jim dali enkratni peroralni odmerek radioaktivnega doksazosina, so ugotovili kopičenje v mleku, kjer je bila najvišja koncentracija približno 20-krat višja od koncentracije v plazmi matere.
Very rare: increase of serum creatinine. 
Zelo redki: zvišane vrednosti kreatinina v serumu
They are available in PVC/PVDC/aluminium blisters packs of 28 tablets [10, 20, 30, 50, 56, 60, 90, 98, 100, 140 (10 x 14) tablets and in HDPE tablet containers of 100, 250 tablets]. 
Na voljo so v pretisnih omotih iz PVC/PVDC/aluminija z 28 tabletami [10, 20, 30, 50, 56, 60, 90, 98, 100 in 140 (10 x 14) tabletami ter v vsebnikih za tablete iz polietilena velike gostote (HDPE) s 100 in 250 tabletami].
• if you have or have had a blockage in your gut 
• če imate ali ste imeli kakršno koli obliko zapore prebavil;
• if you have diabetes 
• _ če imate sladkorno bolezen;
White, round, biconvex tablets with bossing “DL” 
Bele, okrogle, bikonveksne tablete z reliefnim napisom "DL".
Doxazosin may influence plasma renin activity and urinary excretion of vanillylmandelic acid. 
Doksazosin lahko vpliva na aktivnost renina v plazmi in izločanje vanilil-mandljeve kisline z urinom.
LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S)/MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, NAČINOV UPORABE ZDRAVILA, VLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Doxagamma 4 mg prolonged release tablets and associated names is contraindicated during lactation as the medicinal product accumulates in the milk of lactating rats (see section 5.3) and there is no information about the excretion of the medicinal product into human breast milk. 
Zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena je med dojenjem kontraindicirano, ker se zdravilo kopiči v mleku doječih podgan (glejte poglavje 5.3), o izločanju zdravila v mleko pri človeku pa ni podatkov.
Caution is also recommended when doxazosin is administered concomitantly with medicinal products, which may influence hepatic metabolism (e.g. cimetidine). 
Previdnost je priporočljiva tudi, kadar se doksazosin uporablja sočasno z zdravili, ki vplivajo na presnovo v jetrih (npr. cimetidin).
- The scope of the referral was to agree whether Doxagamma 4mg prolonged release tablets differ significantly with regards to the release profile from the originator product with potential for increased incidence of adverse events such as dizziness and hypotension, whether there were significant differences in performance of test batches in the single dose phase of studies 5208 and 1995 and whether the applicant has deviated from CHMP guidelines on the design of the bioequivalence studies, particularly in relation to the effect of food with concern regarding the adequate sensitivity of to detect a difference between products, 
- Namen napotitve je bil doseči soglasje o tem, ali se zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem, kar se tiče profila sproščanja, pomembno razlikuje od originatorjevega zdravila, in ali je možnost pojavov neželenih učinkov, kot so omotica in hipotenzija, morebiti povečana; nadalje ali so bile razlike v rezultatih iz študij 5208 in 1995 testnih serij pri enkratnem odmerjanju pomembne, ter končno ali se je vlagatelj oddaljil od smernic pri oblikovanju bioekvivalenčnih raziskav, zlasti kar se tiče učinka, ki bi ga lahko imela hrana na ustrezno občutljivost za zaznavanje razlik med zdraviloma.
The empty tablet will be passed out in your stools. 
Prazno tableto boste izločili z blatom.
This medicinal product is authorised in the Member States of the EEA under the following names: [See Annex I - To be completed nationally] 
Zdravilo je pridobilo dovoljenje za promet v državah članicah EGP pod naslednjimi imeni: [Izpolni država članica]
Children and adolescents: Doxagamma 4 mg prolonged release tablets and associated names are not recommended for patients under the age of 18 years. 
Otroci in mladostniki: Uporaba zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena pri bolnikih, mlajših od 18 let, se ne priporoča.
• if you need a blood test as Doxagamma 4 mg prolonged release tablets and associated names can affect some test results. 
•_ če potrebujete krvne preiskave, ker lahko zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena vpliva na rezultate nekaterih preiskav.
• medicine containing Dopamine, Metaraminol, Methoxamine, Adrenaline (Epinephrine) cough and cold remedies as they may contain Ephedrine, Phenylephrine. 
• zdravila, ki vsebujejo dopamin, metaraminol, metoksamin, adrenalin (epinefrin); zdravila proti kašlju in prehladu, ker lahko vsebujejo efedrin ali fenilefrin.